{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:26:05Z","timestamp":1770963965205,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1053\/j.seminhematol.2011.03.004","type":"journal-article","created":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T09:43:25Z","timestamp":1304243005000},"page":"S24-S36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"S1","title":["Bendamustine's Emerging Role in the Management of Lymphoid Malignancies"],"prefix":"10.1053","volume":"48","author":[{"given":"Mathias J.","family":"Rummel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie A.","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2011.03.004_bib1","first-page":"33","article-title":"Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases","volume":"87","author":"Chow","year":"2002","journal-title":"Haematologica"},{"issue":"Suppl 13","key":"10.1053\/j.seminhematol.2011.03.004_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/sonc.2002.34873","article-title":"In vitro studies with bendamustine: enhanced activity in combination with rituximab","volume":"29","author":"Rummel","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s004320000180","article-title":"Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia","volume":"127","author":"Kath","year":"2001","journal-title":"J Cancer Res Clin Oncol"},{"issue":"Suppl 13","key":"10.1053\/j.seminhematol.2011.03.004_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/sonc.2002.34875","article-title":"Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives","volume":"29","author":"Aivado","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00432-002-0378-6","article-title":"High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas","volume":"128","author":"Bremer","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib6","first-page":"1357","article-title":"Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I\/II study of the German CLL Study Group","volume":"90","author":"Bergmann","year":"2005","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00432-005-0050-z","article-title":"Phase-I\/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy","volume":"132","author":"Lissitchkov","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"issue":"suppl 4","key":"10.1053\/j.seminhematol.2011.03.004_bib8","article-title":"Bendamustine vs fludarabine as second-line treatment for patients with chronic lymphocytic leukemia\u2014first interim results of a randomized study","volume":"19","author":"Niederle","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib9","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Knauf","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib10","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/1042819031000123546","article-title":"Bendamustine plus mitoxantrone\u2014a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I\/II study","volume":"45","author":"Koppler","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib11","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.330.330","article-title":"Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicenter phase II trial of the German CLL Study Group (GCLLSG)","volume":"112","author":"Fischer","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib12","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1080\/10428190400004521","article-title":"Bendamustine\/mitoxantrone\/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies","volume":"45","author":"Weide","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib13","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.205.205","article-title":"Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG)","volume":"114","author":"Fischer","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.2449.2449","volume":"116","author":"Knauf","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib16","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(96)91681-5","article-title":"Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia","volume":"347","author":"Johnson","year":"1996","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib17","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","article-title":"Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients","volume":"98","author":"Leporrier","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib18","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/asheducation-2009.1.440","article-title":"State-of-the-art treatment of chronic lymphocytic leukemia","author":"Hallek","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.325.325","volume":"112","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/1078-0432.CCR-07-1371","article-title":"Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication","volume":"14","author":"Bosch","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib22","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V92.4.1165","article-title":"Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy","volume":"92","author":"Keating","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib23","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib24","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1200\/JCO.1995.13.9.2431","article-title":"Infectious and immunosuppressive complications of purine analog therapy","volume":"13","author":"Cheson","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib25","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.1158\/1078-0432.CCR-08-0388","article-title":"Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling","volume":"14","author":"Roue","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib26","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2008.17.2619","article-title":"Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Foon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib27","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00001813-200110000-00003","article-title":"Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas","volume":"12","author":"Heider","year":"2001","journal-title":"Anticancer Drugs"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","article-title":"Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study","volume":"116","author":"Kahl","year":"2010","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib30","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1080\/1042819042000223822","article-title":"Fludarabine and bendamustine in refractory and relapsed indolent lymphoma\u2014a multicenter phase I\/II trial of the East German Society of Hematology and Oncology (OSHO)","volume":"45","author":"Koenigsmann","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib31","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib32","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib33","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/10428190701361828","article-title":"High anti-lymphoma activity of bendamustine\/mitoxantrone\/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas","volume":"48","author":"Weide","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib34","volume":"116","author":"Rummel","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib35","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.405.405","volume":"114","author":"Rummel","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00432-005-0023-2","article-title":"Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)","volume":"132","author":"Herold","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib37","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","article-title":"Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab","volume":"23","author":"Horning","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib38","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib39","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.385.385","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas\u2014first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)","volume":"110","author":"Rummel","year":"2007","journal-title":"Blood"},{"issue":"15s","key":"10.1053\/j.seminhematol.2011.03.004_bib40","article-title":"Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy","volume":"28","author":"Salles","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib41","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib42","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib43","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2011.03.004_bib44","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"issue":"suppl","key":"10.1053\/j.seminhematol.2011.03.004_bib45","article-title":"Efficacy and safety of bendamustine and rituximab in the treatment of indolent and mantle cell lymphomas in older patients","volume":"26","author":"Rummel","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15s","key":"10.1053\/j.seminhematol.2011.03.004_bib46","article-title":"Bendamustine\/rituximab in relapsed or refractory diffuse large B-cell lymphoma","volume":"28","author":"Vacirca","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196311000266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196311000266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:20:48Z","timestamp":1758522048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196311000266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":46,"alternative-id":["S0037196311000266"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2011.03.004","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bendamustine's Emerging Role in the Management of Lymphoid Malignancies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2011.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}